Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Nivolumab/Ipilimumab Misses Coprimary Endpoint in Adjuvant Melanoma Trial

Gina Columbus @ginacolumbusonc
Published: Wednesday, Nov 20, 2019

Nivolumab is currently approved by the FDA as a single agent or in combination with ipilimumab for patients with unresectable or metastatic melanoma.

Single-agent nivolumab is also indicated for patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection in the adjuvant setting. Moreover, ipilimumab monotherapy is approved by the FDA for the adjuvant treatment of patients with stage III melanoma with pathologic involvement of regional lymph nodes >1 mm who have undergone complete resection including total lymphadenectomy, and also for patients with unresectable or metastatic melanoma in adult and pediatric patients.

References

  1. Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1%. Bristol-Myers Squibb. Published November 20, 2019. https://bit.ly/2D3mU3n. Accessed November 20, 2019.
  2. Eroglu, Z. Mature results of combination nivolumab (NIVO) plus ipilimumab (IPI) as adjuvant therapy in stage IIIC/IV melanoma (MEL). Presented at: 2017 World Congress of Melanoma; October 18-21, 2017; Brisbane, Australia. Presentation SMR09-6.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x